Diagnostic criteria for blepharospasm: A multicenter international study.


Journal

Parkinsonism & related disorders
ISSN: 1873-5126
Titre abrégé: Parkinsonism Relat Disord
Pays: England
ID NLM: 9513583

Informations de publication

Date de publication:
10 2021
Historique:
received: 12 05 2021
revised: 22 08 2021
accepted: 06 09 2021
pubmed: 29 9 2021
medline: 9 2 2022
entrez: 28 9 2021
Statut: ppublish

Résumé

There are no widely accepted criteria to aid the physician in diagnosing BSP. To validate recently proposed diagnostic criteria for blepharospasm in a larger and geographically diverse population and to develop a screening system for blepharospasm. Video-recordings from 211 blepharospasm patients and 166 healthy/disease controls were examined by 8 raters. Agreement for presence of orbicularis oculi spasms, sensory trick, and increased blinking was measured by k statistics. Inability to voluntarily suppress the spasms was asked by the examiner but not captured in the video. Patients/controls were also requested to fill a self-administered questionnaire addressing relevant blepharospasm clinical aspects. The diagnosis at each site was the gold standard for sensitivity/specificity. All the study items yielded satisfactory inter/intra-observer agreement. Combination of items rather than each item alone reached satisfactory sensitivity/specificity. The combined algorithm started with recognition of spasms followed by sensory trick. In the absence of a sensory trick, including "increased blinking" or "inability to voluntarily suppress the spasms" or both items yielded 88-92% sensitivity and 79-83% specificity. No single question of the questionnaire yielded high sensitivity/specificity. Serial application of the questionnaire to our blepharospasm and control subjects and subsequent clinical examination of subjects screening positive by the validated diagnostic algorithms yielded 78-81% sensitivity and 83-91% specificity. These results support the use of proposed diagnostic criteria in multi-ethnic, multi-center cohorts. We also propose a case-finding procedure to screen blepharospasm in a given population with less effort than would be required by examination of all subjects.

Sections du résumé

BACKGROUND
There are no widely accepted criteria to aid the physician in diagnosing BSP.
OBJECTIVE
To validate recently proposed diagnostic criteria for blepharospasm in a larger and geographically diverse population and to develop a screening system for blepharospasm.
METHODS
Video-recordings from 211 blepharospasm patients and 166 healthy/disease controls were examined by 8 raters. Agreement for presence of orbicularis oculi spasms, sensory trick, and increased blinking was measured by k statistics. Inability to voluntarily suppress the spasms was asked by the examiner but not captured in the video. Patients/controls were also requested to fill a self-administered questionnaire addressing relevant blepharospasm clinical aspects. The diagnosis at each site was the gold standard for sensitivity/specificity.
RESULTS
All the study items yielded satisfactory inter/intra-observer agreement. Combination of items rather than each item alone reached satisfactory sensitivity/specificity. The combined algorithm started with recognition of spasms followed by sensory trick. In the absence of a sensory trick, including "increased blinking" or "inability to voluntarily suppress the spasms" or both items yielded 88-92% sensitivity and 79-83% specificity. No single question of the questionnaire yielded high sensitivity/specificity. Serial application of the questionnaire to our blepharospasm and control subjects and subsequent clinical examination of subjects screening positive by the validated diagnostic algorithms yielded 78-81% sensitivity and 83-91% specificity.
CONCLUSION
These results support the use of proposed diagnostic criteria in multi-ethnic, multi-center cohorts. We also propose a case-finding procedure to screen blepharospasm in a given population with less effort than would be required by examination of all subjects.

Identifiants

pubmed: 34583301
pii: S1353-8020(21)00333-3
doi: 10.1016/j.parkreldis.2021.09.004
pmc: PMC9048224
mid: NIHMS1797805
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109-114

Subventions

Organisme : NIGMS NIH HHS
ID : R01 GM109899
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS116025
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001449
Pays : United States
Organisme : NCATS NIH HHS
ID : U54 TR001456
Pays : United States
Organisme : NINDS NIH HHS
ID : U54 NS065701
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR001448
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS119831
Pays : United States

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Références

J Neurol Neurosurg Psychiatry. 2000 Jun;68(6):738-43
pubmed: 10811697
Mov Disord. 2020 Nov;35(11):2038-2045
pubmed: 32662572
Mov Disord Clin Pract. 2014 Apr 10;1(1):62-66
pubmed: 30363833
Neurology. 2005 Jun 28;64(12):2046-9
pubmed: 15985569
J Neurol Neurosurg Psychiatry. 2020 Mar;91(3):314-320
pubmed: 31848221
Toxins (Basel). 2021 Jan 08;13(1):
pubmed: 33430071
J Clin Neurosci. 2004 Feb;11(2):142-4
pubmed: 14732372
J Neurol Neurosurg Psychiatry. 2014 Sep;85(9):987-93
pubmed: 24487380
Mov Disord. 2017 Apr;32(4):498-509
pubmed: 28186662
Mov Disord. 2006 Apr;21(4):571-5
pubmed: 16261620
J Neurol Neurosurg Psychiatry. 2008 Apr;79(4):392-6
pubmed: 17635969
Parkinsonism Relat Disord. 2019 Jun;63:221-223
pubmed: 30655163
J Neurol Neurosurg Psychiatry. 2003 Mar;74(3):348-50
pubmed: 12588923
Neurology. 2013 Jun 11;80(24):2236-41
pubmed: 23751916
Parkinsonism Relat Disord. 2020 Nov;80:54-57
pubmed: 32956974
Eur J Neurol. 2013 Apr;20(4):704-7
pubmed: 23216586
Mov Disord. 2013 Jun 15;28(7):863-73
pubmed: 23649720
Neurology. 2013 Jul 16;81(3):236-40
pubmed: 23771487
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Mov Disord. 2010 Mar 15;25(4):407-12
pubmed: 20108367
J Clin Med. 2021 May 21;10(11):
pubmed: 34064035

Auteurs

Giovanni Defazio (G)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy. Electronic address: giovanni.defazio@unica.it.

Hyder A Jinnah (HA)

Department of Neurology and Human Genetics, Emory University, Atlanta, GA, USA.

Alfredo Berardelli (A)

Sapienza University of Rome, Rome, and IRCSS NEUROMED, Pozzilli (Is), Italy.

Joel S Perlmutter (JS)

Washington University in St. Louis, St Louis, MO, USA.

Gamze Kilic Berkmen (GK)

Department of Neurology and Human Genetics, Emory University, Atlanta, GA, USA.

Brian D Berman (BD)

Virginia Commonwealth University, Richmond, VA, USA.

Joseph Jankovic (J)

Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, USA.

Tobias Bäumer (T)

Institute of Systems Motor Science, University of Luebeck, Luebeck, Germany.

Cynthia Comella (C)

Rush University Medical Center, New Philadelphia, OH, USA.

Adam C Cotton (AC)

Department of Neurology and Human Genetics, Emory University, Atlanta, GA, USA.

Tommaso Ercoli (T)

Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Gina Ferrazzano (G)

Sapienza University of Rome, Rome, and IRCSS NEUROMED, Pozzilli (Is), Italy.

Susan Fox (S)

Toronto Western Hospital, University of Toronto, Canada.

Han-Joon Kim (HJ)

Department of Neurology and Movement Disorder Centre, Seoul National University Hospital, Seoul, South Korea.

Emile Sami Moukheiber (ES)

Department of Neurology, Johns Hopkins University, Baltimore, MD, USA.

Sarah Pirio Richardson (SP)

Department of Neurology, University of New Mexico, Albuquerque, NM, USA.

Anne Weissbach (A)

Institute of Systems Motor Science, University of Luebeck, Luebeck, Germany; Institute of Neurogenetics, University of Luebeck, Luebeck, Germany.

Laura J Wrigth (LJ)

Washington University in St. Louis, St Louis, MO, USA.

Mark Hallett (M)

Human Motor Control Section, NINDS, NIH, Bethesda, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH